Delft Instruments (the Netherlands) profits stride ahead:
This article was originally published in Clinica
Delft Instruments (the Netherlands) has reported net profits of Fl 6.9 million ($4.3 million) in 1994, compared with just Fl 0.1 million in 1993. Turnover rose 17% to Fl 453 million, heavily boosted by the acquisition during the year of Dutch cancer therapy company Nucletron (see Clinica No 624, p 12). Delft says 87% of turnover was outside the Netherlands, with fastest growth in the Far East. The medical sector accounted for 58% of sales. The company expects turnover to reach Fl 500 million in 1995 with a widening of profit margins.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.